AstraZeneca PLC stock (US6549022043): Global pharma leader in oncology and rare diseases

AstraZeneca PLC, a leading biopharmaceutical company, continues to drive innovation in oncology, cardiovascular, and respiratory therapies, with key products generating substantial revenue for US investors tracking global healthcare exposure.

AstraZeneca PLC maintains its position as a major player in the global biopharmaceutical sector, focusing on high-growth areas like oncology and rare diseases. The company reported full-year 2025 results in February 2026, showing total revenue of $47.6 billion, up 18% at constant exchange rates, driven by strong sales of oncology drugs such as Enhertu and Imfinzi, according to AstraZeneca IR as of 02/26/2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AstraZeneca PLC
• Sector/industry: Biopharmaceuticals
• Headquarters/country: Cambridge, UK
• Core markets: US, Europe, China
• Key revenue drivers: Oncology, CVRM, R&I
• Home exchange/listing venue: Nasdaq (AZN), LSE
• Trading currency: USD, GBP

AstraZeneca PLC: core business model

AstraZeneca PLC develops and commercializes prescription medicines across three main therapy areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology (R&I). The company invests heavily in R&D, with 2025 expenditures reaching $11.3 billion, representing 24% of revenue, as detailed in its annual report published February 26, 2026, according to AstraZeneca IR as of 02/26/2026. This focus supports a pipeline of over 180 projects, emphasizing precision medicine and novel modalities like antibody-drug conjugates.

Headquartered in Cambridge, UK, AstraZeneca generates about 37% of its revenue from the US market, making it highly relevant for American investors seeking exposure to innovative healthcare. The ADR trades on Nasdaq under ticker AZN, providing easy access via US exchanges.

Main revenue and product drivers for AstraZeneca PLC

Oncology remains AstraZeneca's largest revenue contributor, accounting for 40% of 2025 sales at $19.0 billion, up 25% year-over-year. Blockbuster products include Tagrisso ($6.4 billion), Imfinzi ($4.2 billion), and the recently approved Enhertu, partnered with Daiichi Sankyo, which posted $3.2 billion in global sales for the full year 2025, per the Q4 earnings release on February 26, 2026, via AstraZeneca press release as of 02/26/2026.

CVRM generated $14.5 billion (up 15%), led by Farxiga ($5.9 billion) for heart failure and chronic kidney disease, while R&I contributed $11.8 billion (up 12%), driven by Symbicort and Tezspire. These franchises underscore AstraZeneca's diversification beyond COVID-19 vaccines, which phased out post-2023.

Industry trends and competitive position

The global biopharma market is projected to grow at 6-8% CAGR through 2030, per IQVIA Institute report as of 01/15/2026, with oncology leading due to rising cancer incidence and ADCs. AstraZeneca ranks among the top 10 by market cap, competing with Roche, Pfizer, and Merck, bolstered by its $1 billion+ Phase 3 readouts expected in 2026.

Strategic acquisitions like Alexion (2021) enhanced its rare disease portfolio, now contributing $4.5 billion annually, positioning AstraZeneca strongly in high-margin specialty areas attractive to US institutional investors.

Why AstraZeneca PLC matters for US investors

AstraZeneca's Nasdaq listing (AZN) and 37% US revenue share tie it closely to American healthcare dynamics, including Medicare policies and obesity drug trends impacting CVRM. The stock traded at $78.50 USD on 05/12/2026 on Nasdaq, according to Yahoo Finance as of 05/12/2026, reflecting steady performance amid sector volatility.

With a dividend yield around 2.1% (2025 payout $3.00 ADR equivalent), it appeals to income-focused US portfolios diversified in global pharma.

Conclusion

AstraZeneca PLC demonstrates robust growth through its oncology leadership and diversified portfolio, with 2025 results highlighting resilience in core markets including the US. Ongoing pipeline advancements and strategic partnerships position it well amid biopharma innovation cycles. Investors monitor upcoming trial data and regulatory updates for continued momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.